RecruitingNCT04633655

International CIPN Assessment and Validation Study

International Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Assessment and Validation Study


Sponsor

University of Milano Bicocca

Enrollment

1,000 participants

Start Date

Jun 8, 2020

Study Type

OBSERVATIONAL

Summary

This is an observational study of chemotherapy-induced peripheral neurotoxicity (CIPN) patients to be investigated prospectively in order to assess responsiveness of a set of outcome measures in an international multi-center study.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Subjects must be candidates for neurotoxic chemotherapy at doses expected to be potentially neurotoxic (a list of neurotoxic drugs is provided in Appendix 1).
  • Male and female subjects who are 18 years of age or older.
  • Subjects freely provide informed consent by signing and dating an informed consent form prior to study entry.
  • Subjects must be willing to complete all study-related activities and follow-up visits required by the protocol.

Exclusion Criteria9

  • Subjects presenting with any of the following will not be included in the study:
  • Poor prognosis, with high probability to be unable to complete the planned chemotherapy treatment.
  • Concomitant neurologic conditions (e.g., brain tumor, spinal or brain metastases) that would interfere or complicate the assessments.
  • Severe depression that in the opinion of the Investigator would complicate the assessments.
  • Chronic treatment with antiepileptic drugs, antidepressants and major analgesics, unless stable dosing and conditions have been reached for 3 months prior to entry.
  • Preventive interventions (e.g., antioxidants, cryotherapy, distal pressure).
  • Subjects who are currently receiving another medication other than antineoplastic chemotherapy drugs that has known potential to produce neurologic peripheral nerve toxicity (e.g. metronidazole, isoniazid, amiodarone, antiretroviral medications).
  • Subjects with any other condition, which, in the investigator's judgment, might decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  • Previous neurotoxic chemotherapy.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERoutcome measures for CIPN testing

questionnaires administration, physician based scales for CIPN data collection


Locations(30)

Birmingham School of Nursing, University of Alabama

Birmingham, Alabama, United States

Northside Hospital

Atlanta, Georgia, United States

JHU

Baltimore, Maryland, United States

University of Michigan School of Nursing

Ann Arbor, Michigan, United States

Columbia University Irving Medical Center

New York, New York, United States

Cancer Center/Wexner Medical Center - Ohio State Medical Oncology Division

Columbus, Ohio, United States

Dartmouth-Hitchcock Medical Center

Lebanon, Pennsylvania, United States

University of Vermont Medical Center

Burlington, Vermont, United States

Brain and Mind Center

Sydney, Australia

Dept. of Neurology, Medical University of Vienna

Vienna, Austria

International Centre for Diarrhoeal Disease Research

Dhaka, Bangladesh

Clínica AMO

Salvador, Brazil

The Ottawa Hospital

Ottawa, Canada

Aarhus University Hospital

Aarhus, Denmark

Hôpital Percy

Clamart, France

CHU Dupuytren

Limoges, France

Center for Molecular Medicine

Cologne, Germany

University of Larissa

Larissa, Greece

"Saint Andrew's" State General Hospital

Pátrai, Greece

San Gerardo Hospital

Monza, Mb, Italy

Ospedale Valduce

Como, Italy

Ospedale Policlinico San Martino

Genova, Italy

A.O.U. Policlinico "G. Martino"

Messina, Italy

Padova Hospital

Padova, Italy

Azienda Ospedaliera Universitaria

Verona, Italy

Medical Oncoloy Unit - University of Nairobi

Nairobi, Kenya

Centro Hospitalar Vila Nova de Gaia/Espinho

Vila Nova de Gaia, Portugal

Dong-A University - Internal Medicine Dept.

Busan, South Korea

Hospital Universitari de Bellvitge-ICO L'Hospitalet

Barcelona, Spain

University of Basel - Department of Sport, Exercise and Health

Basel, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04633655